Corticosteroids in Cellulitis: Limited Role with Weak Evidence
Systemic corticosteroids (prednisone 40 mg daily for 7 days) could be considered as adjunctive therapy in nondiabetic adult patients with uncomplicated lower limb cellulitis, but the evidence is weak and the benefit marginal. 1
Guideline Recommendation
The 2014 IDSA guidelines provide a weak recommendation with moderate-quality evidence for considering corticosteroids in nondiabetic adults with cellulitis 1. This recommendation is notably cautious and applies only to a specific subset of patients—explicitly excluding diabetics who may have impaired wound healing and infection control.
Evidence Quality and Clinical Reality
The evidence supporting corticosteroid use remains disappointingly thin:
NSAIDs show more promise than corticosteroids: A 2024 meta-analysis found that oral NSAIDs as adjunct therapy improved early clinical response at day 3 (RR 1.81,95% CI 1.42-2.31), but this benefit disappeared by day 5 2. Importantly, there was insufficient data to support corticosteroids specifically for clinical response.
No sustained benefit demonstrated: The 2010 Cochrane review found only small single studies examining corticosteroids, with insufficient evidence to form conclusions 3.
Potential harm in specific populations: In pediatric orbital cellulitis, corticosteroids were associated with increased risks of surgery (RR 2.08), PICU admission (RR 1.82), and 30-day readmission (RR 2.53) 4. While orbital cellulitis differs from typical lower limb cellulitis, this raises concerns about corticosteroid safety in severe infections.
Clinical Algorithm for Decision-Making
Consider corticosteroids ONLY if:
- Adult patient (not pediatric)
- Non-diabetic
- Uncomplicated lower limb cellulitis
- Severe local inflammation causing significant morbidity
- Already on appropriate antibiotics
Do NOT use corticosteroids if:
- Diabetic patient
- Pediatric patient
- Facial/orbital cellulitis
- Purulent infection or abscess
- Immunocompromised state
- Concern for necrotizing infection
Practical Approach
The standard of care remains antibiotics alone. Beta-lactams (cefazolin, oxacillin, cephalexin) successfully treat 96% of typical cellulitis cases 1. The IDSA guidelines emphasize that cellulitis often worsens initially after starting antibiotics due to pathogen destruction releasing inflammatory enzymes—this is expected and does not require corticosteroids.
If considering corticosteroids: Use prednisone 40 mg daily for 7 days as the evidence-based regimen 1. Monitor closely for treatment failure, as the theoretical concern is that immunosuppression could worsen infection outcomes.
Common Pitfalls
- Mistaking MRSA risk: Typical cellulitis rarely involves MRSA; reserve MRSA coverage for penetrating trauma, IV drug use, or purulent drainage 1
- Overlooking predisposing factors: Address tinea pedis, venous insufficiency, lymphedema, and skin barrier dysfunction—these are more important for preventing recurrence than acute corticosteroid use 1, 5
- Using corticosteroids in diabetics: The guideline explicitly excludes this population due to infection control concerns 1
Clinical Equipoise Exists
Recent surveys show 74.2% of Australasian clinicians are comfortable randomizing patients to corticosteroids, indicating ongoing uncertainty 6. The evidence base remains low to very low certainty across all outcomes 7, 2, 4.
Bottom line: Corticosteroids are not standard therapy for cellulitis. If used at all, restrict to carefully selected nondiabetic adults with severe inflammation, recognizing the evidence is weak and the benefit unproven.